NRX invested $27 million in its subsidiary HOPE therapeutics to fund a nationwide rollup of Interventional Psychiatry Clinics. The agreement includes an immediate $2 million investment with a ...

NRx Pharmaceuticals (NRXP)’ wholly-owned subsidiary Hope Therapeutics signed a Stock Purchase Agreement with Smith & Sauer as the first step in a $27.0M financing to fund the planned acquisition ...

NRx Pharmaceuticals (NRXP) announced that it has entered into a binding agreement for a registered direct offering of its common stock with expected gross proceeds of $3.5M with certain ...

NRx Pharmaceuticals (NASDAQ:NRXP) stock rallied 35% Monday after its subsidiary HOPE Therapeutics announced the signing of a binding term sheet with Smith & Sauer for $25M in equity purchases to ...

NRx Pharmaceuticals, Inc. (NRXP) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life ...

Ascendiant Capital Markets increased their price target on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd.

Short interest in NRX Pharmaceuticals Inc (NASDAQ:NRXP) increased during the last reporting period, rising from 643.00K to 1.21M. This put 11.81% of the company's publicly available shares short.

Find the latest NRX Pharmaceuticals, Inc. NRXP analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.